Literature DB >> 16190935

Reversible cytotoxic edema in the splenium of the corpus callosum related to antiepileptic treatment: report of two cases and literature review.

Olga Prilipko1, Jacqueline Delavelle, Francois Lazeyras, Margitta Seeck.   

Abstract

PURPOSE: Clinically silent lesions localized in the splenium of the corpus callosum (SCC) are a rare finding in the magnetic resonance imaging (MRI) of patients receiving antiepileptic drugs (AEDs). They are usually of benign character but may induce unnecessary complementary examinations if their nature is unrecognized. So far, 22 cases have been described in the literature, for which different etiologies have been proposed. We describe two further cases and discuss the probable lesion etiology.
METHODS: We report two cases including a 25-year-old male patient and a 12-year-old female patient with a transient SCC lesion discovered in the context of a presurgical epilepsy evaluation.
RESULTS: Comprehensive MRIs, including diffusion tensor imaging-based fiber tracking of the lesion, revealed a cytotoxic edema not disrupting neuronal fibers. Serum arginine vasopressin (AVP) measurements revealed an altered secretion during the acute phase in one patient.
CONCLUSIONS: On the basis of our results, we hypothesize that the lesion consists of a cytotoxic edema, possibly induced by abrupt AED concentration changes and associated to alterations of AVP secretion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16190935     DOI: 10.1111/j.1528-1167.2005.00256.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  19 in total

1.  Reversible cytotoxic oedema in the splenium of the corpus callosum related to tetracycline therapy.

Authors:  Barbara Grühbaum; Hans Salzer; Christian Nasel; Isolde Lernbass
Journal:  Pediatr Radiol       Date:  2010-08-06

Review 2.  The corpus callosum: white matter or terra incognita.

Authors:  A Fitsiori; D Nguyen; A Karentzos; J Delavelle; M I Vargas
Journal:  Br J Radiol       Date:  2011-01       Impact factor: 3.039

3.  Focal transient lesion in the splenium of the corpus callosum in three non-epileptic patients.

Authors:  Antônio José da Rocha; Fabiano Reis; Hugo Pereira Pinto Gama; Carlos Jorge da Silva; Flávio Túlio Braga; Antônio Carlos Martins Maia; Fernando Cendes
Journal:  Neuroradiology       Date:  2006-08-30       Impact factor: 2.804

4.  Transient splenial lesion of the corpus callosum in clinically mild influenza-associated encephalitis/encephalopathy.

Authors:  N Bulakbasi; M Kocaoglu; C Tayfun; T Ucoz
Journal:  AJNR Am J Neuroradiol       Date:  2006-10       Impact factor: 3.825

5.  Reversible splenial abnormality in hypoglycemic encephalopathy.

Authors:  Ji Hyun Kim; Jeong Yoon Choi; Seong-Beom Koh; Younghen Lee
Journal:  Neuroradiology       Date:  2006-11-30       Impact factor: 2.804

6.  Diffusion Restricted Lesions in the Splenium of the Corpus Callosum.

Authors:  Alex Förster; Paul Apfaltrer; Mansour Al-Zghloul; Holger Wenz; Angelika Alonso; Christoph Groden
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 7.  Diagnosis and management of Marchiafava-Bignami disease: a review of CT/MRI confirmed cases.

Authors:  Matti Hillbom; Pertti Saloheimo; Shinsuke Fujioka; Zbigniew K Wszolek; Seppo Juvela; Maurizio A Leone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-08-26       Impact factor: 10.154

8.  Reversible splenial lesion syndrome in neuroleptic malignant syndrome.

Authors:  Sa Al-Edrus; R Norzaini; R Chua; Sd Puvanarajah; M Shuguna; S Muda
Journal:  Biomed Imaging Interv J       Date:  2009-10-01

9.  Commentary.

Authors:  Erika Celis-Aguilar
Journal:  J Neurosci Rural Pract       Date:  2013-07

10.  Unusual combination of reversible splenial lesion and meningitis-retention syndrome in aseptic meningomyelitis.

Authors:  Nida Tascilar; Hande Aydemir; Ufuk Emre; Aysun Unal; H Tugrul Atasoy; Sureyya Ekem
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.